Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Alvotech (NasdaqGM:ALVO) develops and manufactures biosimilar medicines across autoimmune, eye, bone disorder, and cancer indications, and its stock performance has been mixed over different recent periods.
The share price was flat over the past day, with a 6.4% decline over the past week. Over the past month the stock shows an 8.7% gain, while the past 3 months reflect a 36.6% decline.
Year to date, Alvotech has a 32.4% decline, and the 1 year total return stands at a 57.4% decline. Over a longer period, total return over the past 3 years is a 65.5% decline, and over 5 years a 66.1% decline.
See our latest analysis for Alvotech.
The latest 30 day share price return of 8.7% contrasts with a 1 year total shareholder return decline of 57.4%. This suggests short term momentum has picked up while longer term performance remains weak. Recent moves likely reflect changing views on Alvotech’s biosimilar pipeline and risk profile rather than any single event.
If you are weighing opportunities in healthcare focused names, it can be useful to compare Alvotech with other companies exposed to artificial intelligence in medicine via the 33 healthcare AI stocks
With Alvotech trading at US$3.38 and sitting at a large discount to analyst targets and some intrinsic value estimates, is the market overlooking its biosimilar pipeline, or already pricing in all the future growth that matters?
Alvotech’s most followed narrative pegs fair value at $14.00 per share versus the last close at $3.38. This frames a wide gap that hinges on execution of its biosimilar pipeline and long term earnings plan.
Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.
Want to see what sits behind that valuation gap? The narrative leans on brisk revenue expansion, rising margins and a rich earnings multiple that usually belongs to higher growth names.
Result: Fair Value of $14.00 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that upside story leans heavily on timely regulatory approvals and partner execution, where delays or contract issues could quickly reset expectations and pressure sentiment.
Find out about the key risks to this Alvotech narrative.
With mixed signals across returns and expectations, it can be helpful to look past the headlines and into the details so you can move quickly and form your own view using the 3 key rewards and 3 important warning signs.
If Alvotech has your attention, do not stop there. Use focused stock lists to compare opportunities, pressure test your thinking, and avoid leaving good ideas on the table.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com